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Introduction:This study aims to first discover plasmaproteomic biomarkers relating to
neurodegeneration (N) and vascular (V) damage in cognitively normal individuals and
second to discover proteins mediating sex-related difference in N and V pathology.
Methods: Five thousand and thirty-two plasma proteins were measured in 1061 cog-
nitively normal individuals (628 females and 433males), nearly 90%ofwhomhadmag-
netic resonance imaging measures of hippocampal volume (as N) and white matter
hyperintensities (as V).
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
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Economic andSocial ResearchCouncil;
Alzheimer’sResearchUK Results: Differential protein expression analysis and co-expression network analysis
revealed different proteins and modules associated with N and V, respectively. Fur-
thermore, causal mediation analysis revealed four proteins mediated sex-related dif-
ference in N and one protein mediated such difference in V damage.
Discussion:Once validated, the identified proteins could help to select cognitively nor-
mal individuals with N and V pathology for Alzheimer’s disease clinical trials and pro-
vide targets for further mechanistic studies on brain sex differences, leading to sex-
specific therapeutic strategies.
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1 INTRODUCTION
The National Institute on Aging and Alzheimer’s Association (NIA-AA)
have proposed classifying Alzheimer’s disease (AD) based on biomark-
ers of amyloid pathology (A), tau pathology (T), and neurodegeneration
(N).1 The flexibility of the AT(N) system could be expanded to incor-
porate new biomarkers that track brain vascular (V) damage, leading
to ATV(N).1 Both neurodegeneration and vascular pathology can be
measured by several differentmagnetic resonance imaging (MRI) mea-
sures. For example, neurodegeneration can bemeasured by brain atro-
phy. Multiple lines of evidence showed that hippocampal atrophy is
closely associated with AD.2–4 Vascular pathology can be measured
bywhitematter hyperintensities (WMHs), which have been associated
with an increased risk for developing AD and dementia.5–7
There is increasing evidence to suggest an influence of biological sex
on neuroimaging biomarkers in AD pathogenesis. For example, brain
atrophy rates for those with mild cognitive impairment (MCI) and AD
dementia were faster in females compared to males.8–11 In contrast,
increased WMHs led to faster progression to MCI or AD only among
males.12,13 Although the differences are likely due to sex hormones,14
the exact mechanisms that underlie these sex-related differences are
still unclear. Gaining a more detailed picture of the causes of sex-
related differences could yield important clues about the pathophysi-
ology of AD and eventually lead to sex-specific preventative or thera-
peutic strategies.
Compared toMRImeasures, blood-based biomarkers showpromise
as a simple and potentially cost-effective option for the early detec-
tion, classification, and monitoring of AD pathology. With this in mind,
the present study had two main objectives: first, to identify plasma
biomarkers related to neurodegeneration and vascular pathology in
cognitively normal individuals; second, to identify proteins mediating
sex-related differences in neurodegeneration and vascular damage.
To do this, we used SomaLogic’s Somascan assay to measure 5032
proteins in plasma from 1061 cognitively healthy individuals. Using a
range of statistical approaches, we identified different proteins asso-
ciated with markers of neurodegeneration and vascular damage. Fur-
thermore, using causal mediation analysis, we found evidence for sev-
eral proteins that may mediate sex-related differences in neurodegen-
eration and vascular pathology (Figure 1).
2 METHODS
2.1 Participants
The participants in this study were recruited as part of the Stratify-
ing Resilience and Depression Longitudinally (STRADL) study, which
re-contacted participants from theGeneration Scotland: Scottish Fam-
ily Health Study (GS). The GS study is a large, family-structured,
population-based cohort study of more than 24,000 individuals from
across Scotland. Recruitment took place between 2006 and 2011with
a clinical visit during which detailed health and cognitive test data
were collected along with biological samples (blood, urine, saliva).
Full details of the STRADL cohort and GS protocol are published
elsewhere.15–17 Briefly, blood was collected by venepuncture into
standard polypropylene ethylenediaminetetraacetic acid (EDTA) test
tubes followed by centrifugation; the obtained plasma was aliquoted
in 500 μL aliquots, and stored at −20◦C for future analyses.17 Ethical
approval for STRADL was formally obtained from the National Health
Service Tayside committee and all participants provided their written
informed consent.
We selected a total of 1061 cognitively normal individuals including
628 females and 433 males from STRADL study. Plasma and general
demographic informationwere available for all subjects (including fam-
ily history of AD and apolipoprotein E [APOE] ε4 genotype data). Four
cognitive tests coveringmultiple cognitive domainswere also assessed
for each subject. These tests included digit symbol, verbal fluency, Mill
Hill vocabulary scale, and Wechsler memory test.15 A general cogni-
tive ability score was generated via extracting the first unrotated com-
ponent from a principal component analysis of the four tests. Brain
structural MRI scans were available for 927 participants to obtain
hippocampal volume. Visually inspecting and rating fluid-attenuated
inversion recovery (FLAIR) scans were available for 940 subjects to
obtain Fazekas score, an index ofWMHs.
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F IGURE 1 Overview of the study design: 5032 proteins weremeasured in 1061 cognitively normal individuals who hadmagnetic resonance
imaging (MRI) measurement. Proteome-wide association study ofMRI and protein co-expression network analysis revealed potential proteins for
causal mediation analysis, leading to the finding of proteins mediating sex-related differences in brain neurodegeneration and vascular damage
2.2 Plasma analyses
Plasma proteins were measured using the SOMAscan assay platform
(SomaLogic Inc.). SOMAscan is anaptamer-basedassayallowing for the
simultaneous measurement and quantification of, in the version used
here, 5032 proteins. The assay uses chemicallymodified nucleotides to
transform a protein signal into a nucleotide signal that can be quanti-
fied using relative fluorescence onmicroarrays.18 Raw data processing
and initial quality control (QC) led to 4235 proteins for final analysis.
The abundance of each protein was log-transformed, then the effects
of sample collection site and plasma storage time on proteins were
removed by linear regression and the residuals were used for all sub-
sequent analyses.
2.3 MRI acquisition and analyses
Participants were scanned at two centers: the Ninewells Hospital in
Dundee and at the Aberdeen Royal Infirmary in Aberdeen. Partici-
pants inDundeewere scannedusing aSiemens3TPrisma-FIT (Siemens
Healthineers) with a 20-channel head and neck coil and a back-facing
mirror (software version VE11, gradient with max amplitude 80 mT/m
and maximum slew rate 200 T/m/s). In Aberdeen, participants were
imaged on a 3 T Philips Achieva TX series MRI system (Philips Health-
care) with a 32-channel phased-array head coil with a back-facing mir-
ror (software version 5.1.7; gradients with maximum amplitude 80
mT/m and maximum slew rate 100). Both study centers followed the
same protocol including structural sequences.17 3T MRI scans were
anonymized at the timeof acquisition and scanning sitewas included as
a covariate in statistical analyses. Full details of the imaging sequences
and parameters are published elsewhere.19
2.3.1 Hippocampal volume
T1 structural measures were processed using FreeSurfer version 5.320
to quantify the volumes of 14 subcortical structures as well as the vol-
umes, surface area, and thickness of 34 cortical regions per hemisphere
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RESEARCH INCONTEXT
1. Systematic review: Plasma proteins are studied as can-
didate biomarkers to predict brain neurodegeneration
and vascular pathology in Alzheimer’s disease (AD), while
few studies focus on prodromal stage of AD. Further-
more, there is increasing evidence to suggest brain sex
differences in AD pathogenesis, while the exact mecha-
nisms that underlie these sex-related differences are still
unclear.
2. Interpretation: Our findings offer new insights into
changes in individual proteins and protein networks
linked to neurodegeneration and vascular pathology in
the prodromal stage of AD. Furthermore, we identified
several plasma proteinsmediated sex-related differences
in brain neurodegeneration and vascular damage. Our
study is the largest plasma proteomic study in prodromal
AD in terms of the number of proteins assayed and sam-
ple size, to our knowledge.
3. Future directions: It suggests that blood proteins can
predict brain neurodegeneration and vascular pathology
in the prodromal stage of AD. Furthermore, the nomi-
nated proteins are tractable targets for furthermechanis-
tic studies on brain sex differences, with potential to lead
tomore effective sex-specific preventative or therapeutic
strategies.
according to the Desikan-Killany atlas.21 Full details of the FreeSurfer
QC steps are published elsewhere.19 Measures of thickness, surface
area, and volume were derived for each of the 68 cortical regions.
The volumes of 14 subcortical structures—left and right accumbens
area, amygdala, caudate nucleus, hippocampus, pallidum, putamen, and
thalamus—were also extracted from FreeSurfer output. Global mea-
sures of cortical volume, surface area, and thickness were also derived,
as well as five summed lobar measures (frontal, parietal, temporal,
occipital, and cingulate). The number of QC edits made per individual
were recorded to use as a covariate in statistical analyses. Among all
those measures, only hippocampal volume data are used in this study
as it is highly related to AD.2–4
2.3.2 WMHs—Fazekas scores
WMHswas calculated using FLAIR scan files. It was defined as punctu-
ate, focal, or diffuse lesions in the deep or periventricular whitematter,
basal ganglia, or brainstem, visible as areas of hyperintensity on FLAIR
imageswith respect tonormal-appearingwhiteor graymatter. Severity
of WMHs was graded according to the Fazekas scale,22 which distin-
guishes periventricularWMHs and deepWMHs and grades them from
0 (absent) to 3 (severe). A score of 1 is defined as caps or pencil thin
lining (periventricular WMHs, Figure S1A1 in supporting information)
or punctuate foci (deep WMHs, Figure S1B1); a score of 2 is defined
as a smooth halo (periventricularWMHs, Figure S1A2) or beginning to
confluence (deep WMHs, Figure S1B2) and a score of 3 is defined as
irregular periventricular signal extending into the deep white matter
(periventricular WMHs, Figure S1A3) or large confluent areas (deep
WMHs, Figure S1B3). We used the total scores in this study by sum-
ming the periventricular and deepwhite matter scores.
2.4 Statistical analysis
Statistical analyseswere completed usingR (version 3.3.2). To compare
baseline cohort characteristics between males and females, we used
Mann-Whitney U tests and Chi-square tests to compare continuous
and binary variables, respectively.
2.4.1 Protein differential expression analysis (DEA)
We used partial Spearman correlation to test the association of pro-
teins with hippocampal volume andWMHs (Fazekas scores), adjusting
for age, sex, and APOE ε4 genotype. Additionally, imaging batch, num-
ber of image edits per individual, assessment center, and standardized
intracranial volume (ICV) were set as covariates for hippocampal vol-
ume analyses. We performed such analyses in all individuals as well as
in subgroups stratified by sex. P valueswere corrected using a false dis-
covery rate (FDR) formultiple testing. Proteins that were differentially
expressed at a nominal significance level of P < .05 were included in
pathway analysis using WebGestalt software (http://www.webgestalt.
org/). Briefly, differentially expressed proteins were included as the
“protein list” and all proteins measured by SOMAscan assay were used
as “background.” This enrichment analysiswas performedon theKyoto
Encyclopedia of Genes and Genomes (KEGG) database.
2.4.2 Weighted gene correlation network analysis
(WGCNA)
We first used the R package WGCNA23 to construct a co-expression
network from the proteins. The effects of age and sex on proteins
were adjusted for by linear regression and the resulting residuals were
used for analysis. WGCNA clustering is based on calculating corre-
lations between paired variables, soft-threshold transforming them
with a power function (corβ), and using the result as adjacency matrix
between variables. The final step applies hierarchical clustering to this
adjacency matrix. We applied this algorithm with default parameters,
except for the following settings: soft threshold power beta = 4, min-
imum module size = 10 proteins, merge cut height = 0.2. The result-
ing modules or groups of co-expressed proteins were used to calcu-
latemodule eigenproteins. The eigenprotein-based connectivity (kME)
was used to represent the strength of a protein’s correlationwith other
protein module members. Proteins with high intramodular kME in the
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TABLE 1 Demographics of participants included in the analysis by sex
Characteristics Female (n= 628) Male (n= 433) P value
Agemean (SD), y 59.3± 9.7 60.7± 9.3 0.02
APOE ε4+N (%) 170 (27%) 118 (27%) 0.99
Educationmean (SD), y 4.5 (1.5) 4.5 (1.6) 0.83
Mother with AD 46 (7.3%) 27 (6.2%) 0.57
Father with AD 24 (3.8%) 15 (3.5%) 0.89
Hippocampal volume (SD) in mm3 8155 (744) 8659 (936) <0.001
WMHs (SD) 2.27 (0.92) 2.21 (0.88) 0.35
Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; SD, standard deviation;WMHs, whitematter hyperintensities.
Note: Percentage of cases is shown in parentheses for APOE ε4 carriers andmother or father with AD.
top 90th percentile within a module were considered hub proteins.
KEGG pathway enrichment was performed for each module using
WebGestalt software as described previously. Briefly, proteinswithin a
module were assembled into a “protein list” and all proteins were used
as “background.”
We then calculated the association of eigenproteinswith hippocam-
pal volume and WMHs in all individuals as well as in only female
and male individuals, adjusting for age, sex, and APOE ε4 genotype.
The additional covariates for hippocampal volumewere imaging batch,
number of image edits per individual, assessment center, and ICV. The
P values were corrected with FDR and corrected P values were pre-
sented in a heatmap. Furthermore, we used Student’s t-test to assess
pairwise difference of eigenproteins among different AD risk groups.
The AD risk was decided by both family history and APOE ε4 genotype.
In detail, individuals without family history (self-reported as no parent
with AD) and without a copy of the APOE ε4 allele were categorized as
low risk; individuals with either family history or APOE ε4were defined
as being at medium risk; individuals with both were classified as high
risk.
2.4.3 Causal mediation analysis
We used R package regmedint24 to investigate how the relationship
between an exposure variable and anoutcomevariable relate to a third
intermediate variable, namely the mediator. Here, we wanted to test
if proteins (as mediator, M) mediate the relationship between sex (as
exposure, X) andMRI measurement (as outcome, Y). A mediator needs
to meet the following three criteria25 (Figure S2A in supporting infor-
mation): (1) A change in levels of the exposure variable significantly
affects the changes in the outcome (i.e., total effect of X on Y is signif-
icant). (2) There is a significant relationship between the mediator and
the outcome (i.e., Path fromM to Y). (3) A change in levels of the expo-
sure variable significantly affects the changes in themediator (i.e., Path
fromX toM).
There was a significant difference between females and males in
terms of hippocampal volume and WMHs after adjusting for covari-
ates (Figure S2B and C; criteria 1). For mediators, we selected proteins
significantly associated with hippocampal volume or WMHs (criteria
2). We also checked that these proteins are significantly expressed
between females and males (criteria 3). We reported those proteins
whose natural indirect effect is significant and the direction is consis-
tent with natural direct effect.
3 RESULTS
3.1 Subject demographics
Demographic information of subjects is shown in Table 1. The male
group was slightly older than the female group. No significant differ-
ence was observed in the distribution of APOE ε4 carriers, education,
and self-reported family history (mother or father reported as hav-
ing AD). In terms of MRI measures, females had a smaller hippocam-
pal volume thanmales on average, while no differencewas observed in
WMHs.
3.2 Proteins significantly associated with
hippocampal volume and WMHs
Using partial Spearman correlation, we found nominally significant
associations (P < .05) between 377 proteins and hippocampal volume
in all individuals. Seventeen of these were significant after FDR cor-
rection for multiple testing (FDR P < .05; Figure 2A, Table S1 in sup-
porting information). KEGG pathway analysis of the 228 proteins with
significantly negative associations (P < .05) revealed three pathways
including cytokine–cytokine receptor interaction, axon guidance, and
metabolic pathways (Figure 2B). Conversely, the 149 proteins with sig-
nificantly positive associations (P < .05) indicated two pathways that
were cell adhesion molecules (CAMs) and complement and coagula-
tion cascades (Figure 2B). Stratifying by sex, we found 328 proteins
showed nominally significance in females and 2 of them were signifi-
cant after FDR correction. In contrast, 172 proteins showed nominally
significance in males while no proteins were significant after FDR cor-
rection.
For WMHs, 178 proteins showed nominal significance and 2 of
them remained significant after FDR correction in all individuals
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F IGURE 2 Volcano plot of proteins associated with (A) hippocampal volume and (C) white matter hyperintensities (WMHs). Those proteins
with significantly negative correlations (P< .05) are shown in blue, while the proteins with significantly positive correlations (P< .05) are noted in
red. Enriched Kyoto Encyclopedia of Genes and Genomes pathways of proteins with significantly negative (blue) and positive (red) associations
with (B) hippocampal volume and (D)WMHs. DE, differential expression; FDR, false discovery rate
(Figure 2C, Table S1). KEGG pathway analysis of the proteins with
significantly negative and positive associations (P < .05) revealed one
and five enriched pathways, respectively (Figure 2D). None of the
proteins were significant after FDR correction in either females or
males. Of the 17 hippocampal volume-related and 2 WMH-related
proteins (FDR P < .05), 8 of them were significantly associated with
general cognitive score (Figure S3 in supporting information).
3.3 Plasma protein co-expression network
analysis reveals modules linked to hippocampal
volume and WMHs
We first performed a network-based analysis of the plasma proteome
using WGCNA. We found eight modules (M) of co-expressed proteins
and ranked them based on size from largest (M1 turquoise module;
n = 2694 proteins) to smallest (M8 pink module; n = 13 proteins;
Table S2 in supporting information). Figure 3A shows the clustering of
thesemodules’ concordance according to similarities in expressionpat-
terns.We further investigated the biological significance of proteins in
each module and found that the modules were enriched with various
pathways after FDR correction (Table S3 in supporting information),
such as renal cell carcinoma (M1 turquoisemodule), cytokine–cytokine
receptor interaction (M2 blue module), metabolism of xenobiotics by
cytochrome P450 (M4 yellow module), complement and coagulation
cascades (M5 green module), cholesterol metabolism (M6 red module),
and pancreatic secretion (M8 pinkmodule).
We then assessed the module correlations to hippocampal volume
and WMHs in all individuals as well as only in females and males. As
shown in Figure 3B, across all individuals and after FDR correction,
the M4 yellow and M6 red modules had a negative and positive corre-
lation with hippocampal volume, respectively. Furthermore, such cor-
relations remained significant in males and females and their direction
of association were consistent. In addition, the M5 green module was
positively correlated with hippocampal volume inmales.
ForWMHs, none of themodules passed FDR in all individuals. How-
ever, in females, theM1 turquoise andM6 redmodules had negative cor-
relationswithWMHs. Inmales, theM1turquoiseandM3brownmodules
were positively associatedwithWMHswhile theM5 greenmodule was
negatively associated with WMHs (Figure 3B). Furthermore, modules
that were positively correlated with hippocampal volume were nega-
tively associated with WMHs such as the M5 green and M6 red mod-
ules, indicating the consistency between such associations because
hippocampal atrophy and larger WMHs are associated with increased
AD risk. Figures 3C andD showed the hub proteinswithin theM5green
andM6 redmodules, respectively.
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F IGURE 3 Protein modules correlating to hippocampal volume andwhite matter hyperintensities (WMHs). A,Weighted gene correlation
network analysis (WGCNA) of the plasma proteome. This algorithm generated eight modules (M) of co-expressed proteins. Modules are clustered
in the network dendrogram based on their relatedness. B, Analysis of the association of modules with hippocampal volume andWMHs. * and **
denote significant correlations P< 0.05 and P< 0.001 after false discovery rate (FDR) correction, respectively. (C) and (D) Hub proteins noted
within theM5 green andM6 redmodules, respectively. F, female; M, male; N, neurodegeneration; V, vascular damage
3.4 Correlation of protein networks with
cognitive test scores and AD risk
We further investigated themodule correlations to cognitive testmea-
sures and AD risk. We found that the M4 yellow and M8 pink mod-
ules had negative correlations and M5 green module had a positive
correlation with general cognitive score after FDR correction (Fig-
ure 4A-C). These results are in concordance with MRI correlations
as the M4 yellow and M5 green modules had negative and positive
correlations with hippocampal volume, respectively. The AD risk was
decided by both family history and APOE ε4 genotype as described
previously, leading to 662 low risk, 315 moderate risk, and 32 high
risk individuals. We found that the M2 blue and M6 red modules
showed significant increase and decrease in higher risk compared to
low-risk individuals, respectively (Figure 4D and E). Of these, the M6
red module is in concordance with MRI correlations as it had posi-
tive and negative correlations with hippocampal volume and WMHs,
respectively.
3.5 Causal mediation analysis reveals proteins
mediating brain sex differences
We selected proteins obtained from DEA for further causal media-
tion analysis. Overall, we considered 17 hippocampal volume-related
and two WMH-related proteins (FDR P < .05). Of the 17 proteins, 4
of them showed significant natural indirect effect with hippocampal
volume (Table 2), indicating they mediated sex-related differences in
brain neurodegeneration. Furthermore, two of them were in the M5
green module, which had positive correlations with hippocampal vol-
ume only in males (Figure 3B) and NCAM-1 was the hub protein in
the M5 green module (Figure 3C), further indicating the consistency
8 of 12 SHI ET AL.
F IGURE 4 Protein modules associations with (A-C) general cognitive score and (D-E) Alzheimer’s disease risk
TABLE 2 Mediation of the association between sex andMRI brain variables by proteins
MRImeasures Protein Module Effect estimate [95%CI] P value
Hippocampal volume NCAM-1 Green 0.04 [0.02, 0.07] 0.002
EFEMP1 Green 0.02 [0.003, 0.05] 0.03
R-spondin-1 Turquoise 0.03 [0.01, 0.06] 0.008
FSTL3 Turquoise 0.03 [0.002, 0.05] 0.03
WMHs Apo B Red –0.03 [–0.05, –0.01] 0.008
Abbreviations: CI, confidence interval; MRI, magnetic resonance imaging;WMHs, whitematter hyperintensities.
across DEA and co-expression network analysis. For WMHs, one pro-
tein (ApoB) showeda significant natural indirect effect (Table 2),mean-
ing it mediated sex-related difference in vascular damage. This protein
is in theM6 redmodule, which had a negative correlation with WMHs
only in females (Figure 3B).
4 DISCUSSION
In this study, we used SOMAscan to measure 5032 plasma proteins
from 1061 cognitively normal individuals (female n = 628 and male
n = 433). We performed both proteome-wide DEA and protein co-
expression network analysis to gain insights into changes in individ-
ual proteins as well as networks of proteins relating to neurodegen-
eration and vascular markers in cognitively healthy individuals. We
identified different proteins and modules associated with markers of
neurodegeneration and vascular pathology, respectively. Using causal
mediation analysis, we further confirmed that four proteins medi-
ated sex-related difference in brain neurodegeneration and one pro-
tein mediated such difference in vascular damage. Of the five pro-
teins, three of them were in the modules that were associated with
neurodegeneration or vascular damage only in male or female and
one protein (NCAM-1) was the hub protein in the module, suggest-
ing that our findings are robust across multiple computational anal-
yses. In addition, most neurodegeneration- and vascular pathology–
related proteins and modules were also associated with cognitive
score and their direction of change was in concordance with MRI
correlations.
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It is important to identify blood-based biomarkers relating to neu-
rodegeneration, particularly in the preclinical stage of AD. Most clini-
cal trials for AD have been unsuccessful to date.26 The failure of such
trials was partially caused by the fact that participants enrolled in such
trialswere relatively late in the disease process. Targeting treatment to
earlier pre-symptomatic or prodromal stages of the diseasemight have
more success.27 With this inmindwe sought to identify blood biomark-
ers relating to neurodegeneration in cognitively normal individuals col-
lected from a population-based cohort that resembles the real-world
situation of participants’ recruitment in clinical trials. We identified 17
proteins that were significant after FDR correction formultiple testing
in the full cohort; two proteins were FDR significant in females com-
pared to no proteins in males. This might be because brain atrophy is
small in cognitively normal individuals and that the subgroup analysis is
too small to detect such differences. Nevertheless, because these pro-
teins were associated with neurodegeneration in the preclinical stage,
they could potentially help when recruiting cognitively normal individ-
uals with neurodegeneration for clinical trials with further validation.
The importance of WMHs in AD is increasingly recognized as they
are related to risk for developing AD.5–7 Some studies showed that
there is an association betweenWMHs and AD pathological hallmarks
such as amyloid beta (Aβ) plaques, tau, and neurodegeneration.28–30
Here, we only found two proteins that were associated with WMHs
after FDR correction for multiple testing. This might be because the
participants recruited in our study were relatively young whereas
WMHs tend to be observed with aging.31,32 Current treatment of
WMHs includes pharmacological approaches (i.e., blood pressuremed-
ications and statins)33–35 as well as nonpharmacological approaches
such as lifestyle modifications and risk factor management.36–38 Given
the associations betweenWMHs and vascular risk factors, it is impera-
tive to target vascular health throughout the life course as a prevention
strategy. The proteins identified here could potentially help to select
cognitively normal individuals with vascular pathology at a very early
stage as well as to monitor the intervention outcomes throughout the
life course.
Current findings on the associations of AD hallmarks in plasma
with neurodegeneration and vascular pathology have generated new
enthusiasm. For example, various studies found that neurofilament
light chain (NfL) was closely associated with neurodegeneration.39–41
Furthermore, NfL was also associated with vascular pathology in an
age-dependent manner.42 Another marker, phosphorylated tau (p-
tau)181 was found to be a good marker for predicting and monitoring
neurodegeneration.43,44 These two biomarkers are well recognized as
they have been validated in multiple cohorts across different labora-
tories. In comparison, the identified biomarkers from our study need
further validation in independent longitudinal cohorts. Furthermore, it
is important to conduct head-to-head comparison studies in the future
not only to compare the performance of our identified biomarkers to
both NfL and p-tau181 but also to check whether they could add extra
value on top of these twowell-recognized biomarkers.
The increasing recognition of sex differences in the brain and
AD risk has highlighted the urgent need for biomarkers that more
comprehensively reflect the complex mechanisms underlying these
differences.45,46 Examination of these differences may shed light on
the pathophysiology of AD that differs between the sexes and ulti-
mately lead to more effective interventions and precision medicine.
Here, we reported a study that characterized plasma proteins mediat-
ing brain sex differences in cognitively normal individuals in the largest
sample to date. Using a range of statistical approaches, we identified
four proteins that mediated sex-related difference in brain neurode-
generation and one protein in vascular damage.
Of the five proteins, neural cell adhesion molecule (NCAM) is a part
of a family of cell-surface glycoproteins that play= key roles in nor-
mal brain development, including axonal/dendritic growth and branch-
ing, and synaptic plasticity.47 The levels of NCAM-1 have been shown
to alter in AD patients’ blood, cerebrospinal fluid (CSF), and brain
tissue.48–50 Furthermore, it interacted with amyloid precursor protein
(APP) and promoted neurite outgrowth, indicating that it could be a
potential therapeutic target for AD treatment.51,52 Apolipoprotein B
(Apo B) forms the primary protein component of atherogenic lipopro-
tein particles. Lower levels of this protein was associated with bet-
ter maintenance of cognitive abilities.53 Furthermore, it was highly
associated with Aβ and tau pathology in subjective cognitive decline
individuals, indicating that Apo B may be a potential biomarker for
the preclinical stage of AD.54 R-spondin-1 is encoded by the RSPO1
gene on chromosome 1 and expressed in the central nervous sys-
tem during development.55 This protein has been shown to increase
in CSF of presymptomatic and affected persons carrying familial AD
mutations56 as well as to reduce Aβ and reverse cognitive impairment
in AD mouse model.57 The other two proteins were EGF-containing
fibulin-like extracellular matrix protein 1 (EFEMP1), a member of the
fibulin family that mediates cell–cell and cell–matrix interactions58;
follistatin-related protein 3 (FSTL3), an important physiological regula-
tor of activin; and other TGFβ superfamily members.59 These findings
not only confirm the role of previously reportedproteins inAD, but also
identify new biomarkers relating to early neurodegeneration pathol-
ogy such as EFEMP1 and FSTL3. Furthermore, these findings provide
tractable targets for further mechanistic studies of sex-related neu-
rodegeneration and vascular pathology in the preclinical stage of AD,
eventually leading to sex-specific preventative or therapeutic strate-
gies.
Pathway analysis of hippocampal volume-related andWMH-related
proteins revealed five and six significantly enriched pathways, respec-
tively. Some of them have been reported being associated with AD
such as axon guidance,60 MAPK signaling pathway,61 and cell adhesion
molecules (CAMs),62 further demonstrating the relatedness of these
proteins with AD. Furthermore, most neurodegeneration and vascu-
lar damage-related proteins and proteinmoduleswere associatedwith
cognitive score and their direction of association were in concordance
with brain MRI correlations. Various studies have reported that brain
atrophy and increasedWMHs lead to cognitive decline.63–67 Our find-
ing further demonstrated that proteins relating to brain pathology
were also associated with lower cognitive test scores.
There are three limitations for our study. First, the population in
this study is of European ancestry, predominantly of Scottish ancestry,
so validation in independent cohorts and particularly in other ethnic
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groups is needed to see if the results are generalizable. Second, our
study is cross-sectional and longitudinal studies are required to deter-
mine the role of nominated proteins in sex differences in brain pathol-
ogy and risk of AD. Third, although the individuals in this study are
well characterized on cognition, APOE ε4 genotype, and family history,
there is a lack of Aβ plaques and tau tangles to confirm the stage of AD.
Therefore, the terminology of preclinical AD needs to be interpreted
with caution. Further studies on individuals defined by both neu-
ropathology and clinical symptoms are needed to confirm the results.
Despite this, our study is the largest we are aware of to report
plasma biomarkers indicative of both neurodegeneration and vascu-
lar damage in cognitively normal individuals in terms of the number of
proteins assayed as well as sample size. By applying different statisti-
cal approaches, we identified individual proteins and protein networks
linked to N and V in the poorly understood preclinical stage of AD. Fur-
thermore, we demonstrated that four proteins mediated sex-related
differences in brain neurodegeneration and one protein in vascular
damage. These nominated proteins can not only serve as biomarkers
to help recruit cognitively normal individuals with neurodegeneration
and vascular damage for clinical trials but also as predictive biomarkers
to monitor possible intervention outcomes. Furthermore, these pro-
teins provide tractable targets for further mechanistic studies of sex
differences in brain pathology and AD risk, with potential to lead to
more effective sex-specific preventative or therapeutic strategies.
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